Sinocare Makes a Strong Debut at IDF 2026 in Melbourne

From August 18 to 21, 2026, Melbourne, Australia, hosted IDF-WPR 2026, ADC 2026 & Metabolic Diseases 2026, one of the Southern Hemisphere’s largest diabetes conferences. As a leading global diabetes digital management expert, Sinocare showcased a range of core products and technologies, highlighting its latest innovations in diabetes and chronic disease management and its expanding global presence.

CGM + AI: Turning Data into Actionable Insights

The widespread adoption of continuous glucose monitoring (CGM) has brought 24/7 access to dynamic glucose data, opening new possibilities for diabetes management.

Sinocare’s iCan Continuous Glucose Monitoring System is the world’s first CGM product based on third-generation glucose sensor fabrication technology. It delivers enhanced interference resistance and accuracy comparable to leading products globally. With regulatory approvals and registrations in more than 60 countries and regions, iCan is helping people with diabetes around the world access high-precision glucose monitoring at an affordable cost.

Collecting vast amounts of glucose data is only the beginning. The real value lies in interpreting that data, identifying glucose patterns, anticipating health risks, and translating insights into actionable interventions. Artificial intelligence is becoming a key engine for unlocking the clinical and practical value of CGM data.

Since 2022, Sinocare has been advancing its AI strategy. Built on the iCanNet Trusted Data Space, Sinocare integrates multidimensional health data from home testing, daily behaviors, personal health records, and other sources to develop its proprietary diabetes management AI agent, iCan Coach.

iCan Coach has advanced to Level 5 intelligent guidance, with three core capabilities: AI-powered food recognition, glucose trend prediction, and personalized management recommendations. By shifting health management from reactive intervention to proactive prediction, it enables more personalized care tailored to individual needs.

For international markets, Sinocare is rolling out multilingual versions of iCan Coach. Based on regulatory requirements and market needs in different countries and regions, the company is progressively introducing iCan Coach capabilities for both individual users and healthcare institutions, advancing from a data collection tool to an intelligent diabetes management solution.

Desktop Diagnostics + AI: Bringing Intelligent Decision Support to Primary Care

The benefits of precision medicine depend not only on technological advances, but also on access to diagnostic capabilities. A key question is whether primary care clinics in remote areas can access laboratory-level testing without the complexity of interpreting multiple diagnostic reports.

Sinocare’s iCARE-1300 Portable Fully Automated Multiparameter Analyzer integrates three testing platforms—five-part hematology, liquid-phase biochemistry, and immunoassay—into a compact, desktop-sized system. It brings testing capabilities that traditionally require multiple large-scale instruments into a single device.

Powered by Sinocare’s AI algorithms, iCARE-1300 can intelligently analyze test results, flag abnormal parameters, and provide reference interpretations. This helps reduce the technical barriers to result interpretation and enables primary care facilities to access timely, reliable diagnostic testing and decision support.

By bringing precision diagnostics closer to patients, advanced healthcare is becoming increasingly accessible at the primary care level.

Precision Healthcare Beyond Human Health

As pets become an increasingly important part of family life, demand for pet healthcare continues to grow. At the same time, metabolic conditions such as diabetes are being increasingly recognized in dogs and cats, creating a growing need for long-term monitoring and management.

Building on its extensive expertise in human diabetes monitoring, particularly in CGM, Sinocare is extending its high-precision sensing technologies into the animal health sector. This opens new possibilities for the early screening and long-term management of diabetes and other metabolic conditions in companion animals. The move demonstrates the versatility of Sinocare’s core sensing technologies while extending its vision of whole-life-cycle health management beyond human healthcare and into a broader range of living systems.

From in-hospital diagnosis to self-management at home, from tertiary hospitals in major cities to primary care clinics in remote areas, and from human healthcare to veterinary applications, Sinocare’s presence at IDF 2026 demonstrated a systematic approach to advancing precision healthcare.

Looking ahead, Sinocare will continue to deepen the integration of biosensing, AI, and healthcare, combining AI agents, diabetes and chronic disease expertise, and long-term behavioral management to provide continuous, personalized support. By turning advanced technologies into practical solutions, Sinocare aims to make intelligent health management more accessible and deliver tangible benefits to people around the world.